Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-Guided ATG Dosing in Haploidentical Stem-cell Transplantation
NCT07791576Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin rabbit in graft-versus-host disease (GVHD), sponsored by Chinese PLA General Hospital. Primary endpoint: GVHD-free and relapse-free survival rate at 1 year. Started May 2025; status: recruiting.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07791576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791576.